The Role of Mucosal Healing in the Treatment of Patients With Inflammatory Bowel Disease

作者: Byron P. Vaughn , Sveta Shah , Adam S. Cheifetz

DOI: 10.1007/S11938-013-0008-1

关键词:

摘要: Mucosal healing is a promising therapeutic endpoint in the treatment of inflammatory bowel disease. Currently, IBD focuses predominantly on clinical remission, without requiring demonstration mucosal healing. However, recent studies suggest that achieving engenders better outcomes. In this review, we will examine concept healing, including its definitions and assessment techniques, evaluate data regarding potential benefits IBD. Furthermore, discuss how often can be expected with each therapies for While an ideal outcome, it may not practical or feasible any given patient. Although discussed all patients, practicing physician should realize goal possible manage patient accordingly.

参考文章(74)
D. Laharie, A. Reffet, G. Belleannée, E. Chabrun, C. Subtil, S. Razaire, M. Capdepont, V. de Lédinghen, Mucosal healing with methotrexate in Crohn’s disease: a prospective comparative study with azathioprine and infliximab Alimentary Pharmacology & Therapeutics. ,vol. 33, pp. 714- 721 ,(2011) , 10.1111/J.1365-2036.2010.04569.X
Stephen B Hanauer, William J Sandborn, Christian Dallaire, André Archambault, Bruce Yacyshyn, Chyon Yeh, Nancy Smith-Hall, Delayed-Release Oral Mesalamine 4.8 g/day (800 mg tablets) Compared with 2.4 g/day (400 mg tablets) for the Treatment of Mildly to Moderately Active Ulcerative Colitis: The ASCEND I Trial Canadian Journal of Gastroenterology & Hepatology. ,vol. 21, pp. 827- 834 ,(2007) , 10.1155/2007/862917
Jasvinder A Singh, George A Wells, Robin Christensen, Elizabeth Tanjong Ghogomu, Lara J Maxwell, John K MacDonald, Graziella Filippini, Nicole Skoetz, Damian K Francis, Luciane C Lopes, Gordon H Guyatt, Jochen Schmitt, Loredana La Mantia, Tobias Weberschock, Juliana F Roos, Hendrik Siebert, Sarah Hershan, Chris Cameron, Michael PT Lunn, Peter Tugwell, Rachelle Buchbinder, Adverse effects of biologics: a network meta‐analysis and Cochrane overview Cochrane Database of Systematic Reviews. ,vol. 2011, pp. 1- 58 ,(2011) , 10.1002/14651858.CD008794.PUB2
P. Rutgeerts, K. Geboes, G. Vantrappen, J. Beyls, R. Kerremans, M. Hiele, Predictability of the postoperative course of Crohn's disease Gastroenterology. ,vol. 99, pp. 956- 963 ,(1990) , 10.1016/0016-5085(90)90613-6
B. Landi, T.N'guyen Anh, A. Cortot, J.C. Soule, E. Rene, J.P. Gendre, P. Bories, A. See, E.H. Metman, C. Florent, E. Lerebours, J.Y. Mary, R. Modigliani, Endoscopic monitoring of Crohn's disease treatment: A prospective, randomized clinical trial Gastroenterology. ,vol. 102, pp. 1647- 1653 ,(1992) , 10.1016/0016-5085(92)91725-J
Roopali Bansal Gupta, Noam Harpaz, Steven Itzkowitz, Sabera Hossain, Sierra Matula, Asher Kornbluth, Carol Bodian, Thomas Ullman, Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. ,vol. 133, pp. 1099- 1105 ,(2007) , 10.1053/J.GASTRO.2007.08.001
M F Neurath, New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunology. ,vol. 7, pp. 6- 19 ,(2014) , 10.1038/MI.2013.73
Gianmichele Meucci, Renato Fasoli, Simone Saibeni, Daniela Valpiani, Renzo Gullotta, Enrico Colombo, Renata D'Incà, Maddalena Terpin, Giovanni Lombardi, IG-IBD, None, Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: A prospective, multicenter study Inflammatory Bowel Diseases. ,vol. 18, pp. 1006- 1010 ,(2012) , 10.1002/IBD.21838